Published in Bone on August 11, 2009
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int (2013) 1.79
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. Osteoporos Int (2012) 1.09
Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. Bone (2011) 0.98
Differences in regional bone metabolism at the spine and hip: a quantitative study using (18)F-fluoride positron emission tomography. Osteoporos Int (2012) 0.88
Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab (2010) 0.87
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int (2013) 0.87
PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int (2014) 0.87
Precision of ¹⁸F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. Osteoporos Int (2012) 0.84
A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2014) 0.82
Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. Osteoporos Int (2011) 0.80
Tea and bone health: steps forward in translational nutrition. Am J Clin Nutr (2013) 0.79
Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality. Front Endocrinol (Lausanne) (2015) 0.79
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporos Int (2011) 0.79
Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis. Eur J Nucl Med Mol Imaging (2011) 0.78
Doped tricalcium phosphate scaffolds by thermal decomposition of naphthalene: Mechanical properties and in vivo osteogenesis in a rabbit femur model. J Biomed Mater Res B Appl Biomater (2014) 0.78
The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study. J Bone Miner Metab (2015) 0.77
Validation of urinary calcium isotope excretion from bone for screening anabolic therapies for osteoporosis. Osteoporos Int (2014) 0.77
Early Effects of Single and Low-Frequency Repeated Administration of Teriparatide, hPTH(1-34), on Bone Formation and Resorption in Ovariectomized Rats. Calcif Tissue Int (2015) 0.76
Recombinant PTH: a study of the outcome of teriparatide therapy for 138 patients with osteoporosis. Ulster Med J (2013) 0.76
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int (2016) 0.76
Teriparatide for osteoporosis: importance of the full course. Osteoporos Int (2016) 0.75
Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. J Clin Endocrinol Metab (2015) 0.75
Calcium Supplementation Attenuates Disruptions in Calcium Homeostasis during Exercise. Med Sci Sports Exerc (2017) 0.75
Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem (2016) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med (2011) 2.98
Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med (2012) 2.92
A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res (2004) 2.92
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet (2010) 2.68
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab (2003) 2.54
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab (2010) 2.29
Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum (2008) 2.26
Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res (2004) 2.21
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. N Engl J Med (2016) 2.15
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res (2007) 2.15
Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos (2011) 2.14
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol (2003) 2.13
Is pathology examination useful after early surgical abortion? Obstet Gynecol (2002) 2.12
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res (2004) 2.01
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.98
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis Cartilage (2005) 1.82
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res (2012) 1.70
Impingement in total hip arthroplasty a study of retrieved acetabular components. J Arthroplasty (2005) 1.70
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab (2004) 1.69
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab (2005) 1.68
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Observations on retrieved humeral polyethylene components from reverse total shoulder arthroplasty. J Shoulder Elbow Surg (2010) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Retracted Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA (2011) 1.57
The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res (2002) 1.57
Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res (2005) 1.56
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2007) 1.53
Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res (2011) 1.52
Multicenter implementation of a consensus-developed, evidence-based, spontaneous breathing trial protocol. Crit Care Med (2008) 1.51
Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res (2003) 1.50
Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. J Bone Miner Res (2013) 1.50
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 1.50
Fibromyalgia syndrome. J Rheumatol (2005) 1.49
The DASH diet and sodium reduction improve markers of bone turnover and calcium metabolism in adults. J Nutr (2003) 1.47
Retrieval, experimental, and computational assessment of the performance of total knee replacements. J Orthop Res (2006) 1.47
Supine vs decubitus lateral patient positioning in vertebral fracture assessment. J Clin Densitom (2012) 1.46
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc (2004) 1.44
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone (2009) 1.41
Assessment of fracture risk. Eur J Radiol (2009) 1.40
Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.38
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum (2003) 1.37
Asthma genetics and genomics 2009. Curr Opin Genet Dev (2009) 1.37
Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem (2006) 1.36
Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum (2009) 1.35
Knowledge, attitudes, behaviors, and perceptions of risk related to HIV/AIDS among Chinese university students in Hunan, China. AIDS Patient Care STDS (2005) 1.32
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther (2009) 1.30
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther (2005) 1.30
Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin (2004) 1.28
Bisphosphonates in oncology. Bone (2011) 1.27
Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis (2010) 1.27
Cancellous bone adaptation to tibial compression is not sex dependent in growing mice. J Appl Physiol (1985) (2010) 1.27
Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res (2004) 1.27
Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int (2008) 1.26
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Bone mass is preserved and cancellous architecture altered due to cyclic loading of the mouse tibia after orchidectomy. J Bone Miner Res (2008) 1.25
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 1.24
In vivo cyclic axial compression affects bone healing in the mouse tibia. J Orthop Res (2006) 1.24
In vivo cyclic compression causes cartilage degeneration and subchondral bone changes in mouse tibiae. Arthritis Rheum (2013) 1.24
Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum (2005) 1.24
Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab (2010) 1.21
A nuclear target for interleukin-1alpha: interaction with the growth suppressor necdin modulates proliferation and collagen expression. Proc Natl Acad Sci U S A (2003) 1.21
Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. J Orthop Res (2005) 1.19